EXPRS2 (EXPRS2) News
Follow EXPRS2 (EXPRS2) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ExpreS2ion Biotech Fully Enrolls Phase I Breast Cancer Trial
The ES2B-C001 trial enrolled 19 patients. Preliminary data show anti-HER2 responses in 12 of 13 evaluable patients, with no DLTs or SUSARs. The primary readout is now expected in Q1 2027, shifted from end-2026.
EQUITY | Oct 23, 2026, 08:30 AM UTC
L
Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
ExpreS2ion Biotech Holding AB OMXSTO:EXPRS2
NEWS | Sep 23, 2026, 02:51 PM UTC
L
ExpreS2ion Biotech Holding AB (EXPRS2) Secures ~SEK 19.3M; TO 13 Exercise 1.1%
ExpreS2ion will raise approximately SEK 19.3M before costs via 1.1% TO 13 exercise and a directed share issue under a guarantee, implying about 39.8% dilution once all related shares are registered and issued, subject to
EQUITY | Sep 23, 2026, 02:51 PM UTC
L
ExpreS2ion Biotech Holding AB (publ) (OMXSTO:EXPRS2) Seeks Broad Share Issue Authorization at Oct 1 EGM
ExpreS2ion will hold an Oct 1 EGM to seek authorization for the board to issue shares, convertibles and/or warrants, with or without pre-emptive rights, for cash, in-kind or set-off, within articles-of-association limits
EQUITY | Sep 14, 2026, 08:11 PM UTC
L
Notice to attend an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)
Helsingborg, Sweden, 14 September 2026 - The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby invited to attend an extraordinary general meeting on 1 October 2026 at
NEWS | Sep 14, 2026, 08:10 PM UTC
L
Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)
Helsingborg, Sweden, 14 September 2026 - Aktieägarna i ExpreS2ion Biotech Holding AB (publ), org.nr 559033-3729 ("Bolaget"), kallas härmed till extra bolagsstämma den 1 oktober 2026 klockan 10:00 på Mindpark, Rönnowsgata
NEWS | Sep 14, 2026, 08:10 PM UTC
L
ExpreS2ion Biotech Holding AB Secures SEK 19.3M TO 13 Guarantee, Adds SEK 50M Put Option
ExpreS2ion obtained a ~SEK 19.3M guarantee for its TO 13 warrants and entered a put option deal with Alumni Capital for up to SEK 50M, subject to EGM approval. TO 13 exercise price is SEK 1.60; the put option has a SEK 4
NEWS | Sep 14, 2026, 08:09 PM UTC
H
ExpreS2ion Obtains Commitment for Warrant Program TO 13 and enters into SEK 50 Million Put Option Agreement with lead investor Alumni Capital
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, RUSSIA, SOUTH
GEOPOLITICS | Sep 14, 2026, 08:05 PM UTC
L
ExpreS2ion sets TO 13 warrant exercise price and exercise period
ExpreS2ion announced the exercise price and the start of the exercise period for its TO 13 warrants.
GEOPOLITICS | Sep 02, 2026, 05:45 PM UTC
L
ExpreS2ion to participate in BIO Hong Kong seminar
ExpreS2ion says it will participate in the BIO Hong Kong and H.C. Andersen Capital Institutional Investor Seminar in September.
EQUITY | Aug 31, 2026, 08:00 AM UTC